Children on dialysis who have anemia and require high doses of drugs to treat it are at increased risk of dying prematurely.
Completely correcting anemia in kidney transplant recipients may preserve kidney function better than partially correcting anemia.
When using ESAs to correct anemia in patients with chronic kidney disease, focus less on hitting a given hemoglobin target.
Soluble ferric pyrophosphate significantly decreased ESA use while maintaining target hemoglobin levels without increasing iron stores.
The trend is most pronounced among Medicare recipients since the debut of bundling, ESA labeling changes.
Study also showed an increase in the proportion of patients with hemoglobin level below 10 g/dL and in transfusion rates.
Voluntary recall of anemia drug due to reports of anaphylaxis, including three deaths
Preoperative anemia associated with elevated risk of deaths from other illnesses.
Once-monthly injections of peginesatide are as effective as one to three injections per week of epoetin in maintaining hemoglobin levels.
No major adverse events reported with administering 1.02 grams of ferumoxytol in patients with iron deficiency anemia.
Meta-analysis also reveals an increased risk of vascular access thrombosis, but no increased likelihood of end-stage renal disease.
Hematocrit decreases as estimated glomerular filtration rate (eGFR) declines in hypertensive chronic kidney disease (CKD) patients.
Patients initiating daily hemodialysis (DHD) face a significant decrease in mean hemoglobin (Hb), hematocrit, and transferrin.
Intravenous ascorbic acid (IVAA) can be a potent and effective adjuvant treatment for hemodialysis patients who have normoferritinemic anemia resistant to treatment with erythropoietin (EPO).
Epoetin use and hemoglobin (Hb) levels have declined similarly for black and non-black dialysis patients following the advent of Medicare's system of "bundled" payments.
Iron deficiency in the absence of anemia is associated with intradialytic hypotension (IDH), a finding that suggests iron has a role beyond erythropoiesis.
Clinicians are prescribing less erythropoietin and more intravenous iron for anemic hemodialysis patients after the introduction of a prospective payment system (PPS) for dialysis services ("bundling") and changes to ESA drug labels.
Variant hemoglobin (Hb) is common in African-American hemodialysis patients and it is associated with a need for significantly increased doses of ESA.